The 2023 Global Migraine Research Grant from Pfizer supports migraine research worldwide, specifically:
- Research on the therapeutic application of an oral CGRP antagonist, rimegepant, in migraine, headache, and other diseases where CGRP antagonism may be of clinical benefit
- The development of tools for clinicians and patients to improve the care of migraine patients
- Research regarding health disparities associated with migraine
The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or an advanced degree in Pharmacy, Physiotherapy, Psychology, Social Work or Public Health. Applicant must be affiliated with a host institution. Applicants may apply for up to 500,000 USD, including up to 28% in overhead costs.
Letters of intent have been extended to March 1, 2023. Invited full applications are due in June 2023.